The Galien Foundation, a premier global institution since 1970, heralds a rich legacy of recognising outstanding achievements that improve the global human condition through innovative drugs and other treatments. Created in honour of Galien (129 CE - c. 216), the father of medical science and modern pharmacology, the Prix Galien Award is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

The first edition of this prestigious award is coming to India in partnership with the GM Modi Science Foundation and will be held on March 3rd, 2024, at the Taj Mahal Hotel in New Delhi.

“In the realm of honouring achievements, these awards ensure that our commitment to recognizing greatness resonates with clarity and integrity,” says Padma Bhushan Dr Manju Sharma, Prix Galien India Awards Committee Chair and Former Secretary to the Govt. of India, Department of Biotechnology.

The categories are spread across titles such as Best StartUp and Digital Health Solution; Best Medical Technology; Best Product for Rare/Orphan Diseases; Best Biotechnology Product; Best Academic/Public Sector.

In the previous year in the USA, the awardee for the best biotechnology product was Bristol Myers Squibb’s Camzyos, with Lilly’s Mounjaro and Novo Nordisk’s Ozempic sharing the honour for the best pharmaceutical product. Boehringer Ingelheim’s Spevigo and CSL/uniQure’s Hemgenix won in the rare/orphan disease category.

The awards will be fundamental in recognising and promoting excellence, and through recognition, while enhancing and encouraging a cycle of scientific research excellence and innovation, fostering a culture of innovation that values creative thinking, risk-taking, and the development of solutions that address societal challenges and contribute to economic growth, and showcasing India’s scientific excellence and potential on the international stage.